Novartis accelerates digital transformation with Amazon collaboration

Novartis has entered into a multi-year collaboration with Amazon Web Services (AWS) to reimagine its core pharmaceutical manufacturing, supply chain and delivery options using cloud services.

Core to this collaboration is the creation of Novartis ‘Insight Centers’ that provide real-time visibility across its network of manufacturing operations and distribution centres.

Building on the success of its trial operations centre SENSE, these ‘Insight Centers’ can enable manufacturing and planning teams to better forecast and track production lines, detect potential bottlenecks and then make adjustment recommendations to improve accuracy.

Using AWS, Novartis can collect inventory, quality, and production data across its network and apply AWS Internet of Things (IoT), analytics, and machine learning (ML) services to gain greater visibility and help drive efficiencies.

By centralising this data, Novartis data scientists can also experiment with new optimisation models to help ramp up the production of innovative, personalized treatments that are more complex to make.

In addition, Novartis plans to use AWS IoT services to augment and improve visual inspections of its manufacturing sites by generating images that can be analysed using computer vision algorithms to monitor for risks to manufacturing production, such as unplanned downtime or delayed orders.

With this real-time data, Novartis associates can be better equipped to make data-based decisions that help ensure medicines are efficiently produced and distributed to nearly 1 billion patients in 155 countries around the world.

“Using data science and digital technologies to reimagine the way we manufacture medicines is not only at the heart of our transformation, but also core to our ambition to bring innovative medicines to patients faster,” said Bertrand Bodson, Chief Digital Officer at Novartis.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Sanofi & Translate Bio expand collaboration to develop mRNA vaccines

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio, a clinical-stage messenger RNA (mRNA) therapeutics company, are expanding their existing 2018...

Sarepta & Codiak to research, develop exosome-based therapeutics

Precision medicine specialist, Sarepta Therapeutics, and Codiak BioSciences, a company at the forefront of advancing engineered exosomes as a new class of biologic medicines,...

Gilead acquires equity interest in pioneering immunotherapy company

Gilead Sciences is acquiring a 49.9% equity interest in Pionyr Immunotherapeutics, a privately held San Fran company developing first-in-class cancer immunotherapies. The acquisition – for...

New class of precision medicine strips cancer of its DNA defences

A new precision medicine targeting cancer’s ability to repair its DNA has shown promising results in the first clinical trial of the drug class. The...

Tonix & Southern Research expand COVID-19 vaccine collaboration to include T cell study

New York biopharma, Tonix Pharmaceuticals, has expanded its strategic collaboration with Southern Research to include a study of T cell immune responses to SARS-CoV-2...

Related news

Avalon GloboCare & BOKU to advance intranasal & oral COVID-19 vaccine candidate

Avalon GloboCare, a New Jersey-based clinical-stage global developer of cell-based technologies and therapeutics, has partnered with the University of Natural Resources and Life Sciences...

Sanofi & Translate Bio expand collaboration to develop mRNA vaccines

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio, a clinical-stage messenger RNA (mRNA) therapeutics company, are expanding their existing 2018...

Sarepta & Codiak to research, develop exosome-based therapeutics

Precision medicine specialist, Sarepta Therapeutics, and Codiak BioSciences, a company at the forefront of advancing engineered exosomes as a new class of biologic medicines,...

Gilead acquires equity interest in pioneering immunotherapy company

Gilead Sciences is acquiring a 49.9% equity interest in Pionyr Immunotherapeutics, a privately held San Fran company developing first-in-class cancer immunotherapies. The acquisition – for...